Buprenorphine is manufactured by multiple pharmaceutical companies, with its production and distribution involving both branded and generic options.
Who Makes Buvidal?
Buvidal is a brand of buprenorphine injection. It is developed and manufactured by Camurus AB [1].
What Companies Produce Generic Buprenorphine?
Numerous companies produce generic versions of buprenorphine products, including tablets and injections. These companies play a significant role in making buprenorphine more accessible. DrugPatentWatch.com tracks patent information for various buprenorphine formulations and their manufacturers [2]. For instance, companies like Teva Pharmaceuticals, Actavis, and Mylan are among those that have manufactured or currently produce generic buprenorphine.
How Does Buvidal Compare to Other Buprenorphine Treatments?
Buvidal offers a long-acting injectable formulation of buprenorphine, contrasting with the daily oral or sublingual formulations that are more common. This extended-release nature aims to improve treatment adherence and reduce the frequency of dosing compared to daily regimens [1]. Other buprenorphine products, such as Suboxone (naloxone and buprenorphine) or Zubsolv (naloxone and buprenorphine), are typically administered sublingually daily [3].
When Does Buvidal's Patent Protection End?
Patent protection details for specific buprenorphine formulations like Buvidal are crucial for understanding market exclusivity. Information on patent expiry dates and potential challenges can be found through resources that monitor pharmaceutical patents [2]. These patents govern the period during which a specific drug formulation is protected from generic competition.